The PPARG gene encodes Peroxisome Proliferator-Activated Receptor Gamma¹¹ Peroxisome Proliferator-Activated Receptor Gamma
PPARγ is a nuclear transcription factor that acts as the master regulator of fat cell formation and insulin sensitization, the protein that coordinates adipocyte differentiation and insulin sensitization. It is also the molecular target of thiazolidinedione²² Thiazolidinediones (e.g., pioglitazone, rosiglitazone) are diabetes drugs that bind and activate PPARγ, improving insulin sensitivity drugs used in treating type 2 diabetes. rs17036314 is an intronic variant in PPARG — it does not change the protein sequence itself but sits within a regulatory region of the gene that influences transcriptional output in metabolically active tissues.

The Mechanism

As an intronic variant, rs17036314 likely affects how efficiently or in what pattern PPARG is expressed in insulin-responsive tissues such as skeletal muscle and adipose tissue. The C allele tags a haplotype block in PPARG intron 2 that is associated with higher fasting plasma glucose at baseline and greater risk of progressing from impaired glucose tolerance³³ impaired glucose tolerance
A pre-diabetic state: fasting glucose 100-125 mg/dL or 2-hour post-load glucose 140-199 mg/dL to frank type 2 diabetes. Critically, the risk effect is not fixed: increased aerobic physical activity appears to override the genetic predisposition, restoring normal glucose regulation trajectories in C carriers who become more active.

The Evidence

The primary study is the Finnish Diabetes Prevention Study (DPS), a multi-center randomized trial in which 479 overweight individuals with impaired glucose tolerance were followed for an average of 4.2 years with annual physical activity assessment. Lindi et al. 2007⁴⁴ Lindi et al. 2007
Lindi et al. SNPs in PPARG associate with type 2 diabetes and interact with physical activity. Med Sci Sports Exerc 2008;40(1):25-33 found that C allele carriers had significantly higher fasting glucose at baseline and that the rare C allele predicted conversion to T2D (P = 0.038); uniquely among the seven PPARG SNPs studied, this association remained after adjustment for baseline fasting glucose (P = 0.030). Most importantly, the interaction test between change in physical activity and rs17036314 was highly significant (P = 0.002): participants who substantially increased their activity level showed no excess T2D risk from the C allele, while those who remained sedentary retained the elevated risk.

Although the effect estimate for this intronic variant is modest in cross-sectional GWAS settings, the gene-environment interaction is one of the strongest replicated exercise-by-genotype interactions in the T2D prevention literature. The variant has also been genotyped in a Sudanese candidate-gene study of T2D loci (Mtiraoui et al. 2016⁵⁵ Mtiraoui et al. 2016
Mtiraoui et al. Candidate gene analysis supports a role for polymorphisms at TCF7L2 as risk factors for type 2 diabetes in Sudan. J Diabetes Res 2016), supporting relevance across diverse populations.

Practical Actions

For C allele carriers, the evidence strongly supports aerobic exercise as a primary metabolic intervention — not just for general fitness, but specifically to override the genetic risk this variant confers. The DPS data indicate that increasing total weekly physical activity volume is the lever: participants who moved from low activity to above-median activity abolished the C-allele risk. Monitoring fasting glucose and HbA1c provides objective feedback on whether the intervention is working.

Interactions

rs17036314 shares a gene with rs1801282 (PPARG Pro12Ala), the most studied PPARG variant. In the Finnish DPS, both variants predicted T2D conversion, and both interacted with physical activity. They likely tag different functional haplotypes within PPARG and can compound. The PPARD variant rs2016520 and PPARGC1A rs8192678 (Gly482Ser) operate in the same transcriptional pathway; one study found that combinations of these PPAR-family variants predicted IGT-to-T2D conversion better than any single variant alone.

Your body cannot make DHA from scratch. It relies on a metabolic relay: dietary alpha-linolenic acid (ALA) from plants is converted step by step — first to EPA, then elongated to DPA, and finally to DHA. The last two elongation steps in this relay are performed by ELOVL2, elongation of very long chain fatty acids protein 2¹¹ elongation of very long chain fatty acids protein 2
An endoplasmic reticulum enzyme that catalyses the rate-limiting elongation of EPA (20:5n-3) to DPA (22:5n-3) and then DPA to DHA (22:6n-3). DHA is the dominant structural fatty acid in the brain's grey matter and in photoreceptor cell membranes of the retina. The rs17606561 variant sits in the 3' untranslated region (3'UTR)²² 3' untranslated region (3'UTR)
The non-coding sequence at the end of an mRNA that controls message stability, translation efficiency, and miRNA binding — variants here can alter how much protein a gene produces without changing the protein's sequence of ELOVL2, where it may influence how efficiently the gene is expressed.

The Mechanism

Unlike missense variants that change ELOVL2's protein structure, this 3'UTR variant likely affects gene regulation — potentially altering ELOVL2 mRNA stability or its binding to microRNAs³³ microRNAs
Small non-coding RNA molecules that bind to mRNA 3'UTR sequences and suppress translation or promote degradation, fine-tuning protein output. The net effect is a shift in the EPA→DPA→DHA conversion step. Carriers of the A allele show a pattern consistent with partial ELOVL2 insufficiency⁴⁴ partial ELOVL2 insufficiency
Lower endogenous DHA synthesis capacity, reflected in reduced baseline DHA proportions in plasma phospholipids, with upstream EPA and DPA accumulating or being redirected: lower baseline circulating DHA despite normal EPA intake, with a compensatory up-regulation of the pathway in response to exogenous EPA/DHA — which is why minor allele carriers show a larger DHA response to fish oil supplementation.

The Evidence

The clearest evidence for ELOVL2 variants affecting omega-3 metabolism comes from the CHARGE Consortium meta-analysis⁵⁵ CHARGE Consortium meta-analysis
Lemaitre RN et al. Genetic loci associated with plasma phospholipid n-3 fatty acids: a meta-analysis of genome-wide association studies from the CHARGE Consortium. PLoS Genet, 2011, which examined 8,866 subjects of European ancestry across five cohorts. ELOVL2 minor alleles were robustly associated with higher plasma EPA (p=2×10⁻¹²), much higher DPA (p=1×10⁻⁴³), and significantly lower DHA (p=1×10⁻¹⁵) — a pattern that precisely matches a slowdown at the DPA→DHA elongation step: upstream metabolites accumulate while the downstream product (DHA) is reduced.

A direct supplementation study by Alsaleh and colleagues⁶⁶ Alsaleh and colleagues
Alsaleh A et al. ELOVL2 gene polymorphisms are associated with increases in plasma eicosapentaenoic and docosahexaenoic acid proportions after fish oil supplement. Genes Nutr, 2014 in 310 subjects found that ELOVL2 minor allele carriers had lower baseline plasma DHA but responded more strongly to fish oil supplementation: after 1.8 g/day EPA+DHA, minor allele carriers achieved approximately 30% higher EPA proportions and 9% higher DHA proportions than non-carriers. This paradox — lower baseline, larger response — is consistent with upregulation of an under-expressed enzyme when its substrate (EPA) is sharply increased.

The independent InCHIANTI/GOLDN genome-wide association study Tanaka et al.⁷⁷ Tanaka et al.
Tanaka T et al. Genome-wide association study of plasma polyunsaturated fatty acids in the InCHIANTI Study. PLoS Genet, 2009 also identified the ELOVL2 region as a significant locus for plasma n-3 fatty acid levels in 1,075 elderly Italian subjects, replicated in 1,076 subjects from the GOLDN study.

For rs17606561 specifically, a 2015 birth cohort study Barman et al.⁸⁸ Barman et al.
Barman M et al. Single Nucleotide Polymorphisms in the FADS Gene Cluster but not the ELOVL2 Gene are Associated with Serum Polyunsaturated Fatty Acid Composition and Development of Allergy. Nutrients, 2015 found nominally lower 20:4n-6 in cord serum among rs17606561 carriers, though the association did not survive multiple-testing correction in this smaller cohort (n=211). A Chinese case-control study Sun et al.⁹⁹ Sun et al.
Sun C et al. FADS1-FADS2 and ELOVL2 gene polymorphisms in susceptibility to autism spectrum disorders in Chinese children. BMC Psychiatry, 2018 found nominal association between rs17606561 A allele and autism spectrum disorder risk (OR=1.63, pFDR=0.036), consistent with the known importance of DHA for neurodevelopment, though this requires replication in larger cohorts.

Practical Actions

The key implication is that A allele carriers rely more heavily on preformed DHA from the diet because their endogenous synthesis is less efficient. Plant-based omega-3 sources (flaxseed, chia, walnuts) provide ALA, but the conversion to DHA requires a functional ELOVL2 step that is partially impaired in A allele carriers. Marine-sourced EPA and DHA — from fatty fish or algae-based supplements — bypass this bottleneck entirely.

For heterozygous AG individuals, moderate supplementation with preformed EPA/DHA is advisable. For homozygous AA individuals, the endogenous synthesis impairment is more pronounced; higher intakes of preformed DHA are particularly important, especially for pregnant women (for fetal brain development) and older adults (for retinal and cognitive maintenance).

Interactions

ELOVL2 works in concert with FADS1 and FADS2, which handle the earlier desaturation steps (ALA→SDA→EPA). Variants in FADS1 (rs174547) and FADS2 (rs174537) that reduce desaturase activity compound with ELOVL2 impairment: reduced input to the elongase (less EPA) combined with reduced elongase efficiency creates a double bottleneck for DHA synthesis. Individuals carrying risk alleles in both FADS and ELOVL2 genes have the strongest case for relying on preformed marine DHA rather than plant-based ALA precursors.

TPMT (thiopurine S-methyltransferase) is the enzyme your body uses to inactivate thiopurine drugs¹¹ inactivate thiopurine drugs
Azathioprine, 6-mercaptopurine, and thioguanine — used for inflammatory bowel disease, autoimmune diseases, organ transplantation, and childhood leukemia by methylating them into harmless metabolites. When TPMT activity is reduced, these drugs shunt into an alternative pathway that generates toxic thioguanine nucleotides, which incorporate into DNA and can cause life-threatening bone marrow suppression at standard doses. The TPMT*3B variant (rs1800460) is the decreased-function star allele that, almost always, travels on the same chromosome as TPMT*3C (rs1142345) — and that pair-in-cis is what clinical labs call TPMT*3A, the most common TPMT deficiency haplotype in people of European ancestry.

The Mechanism

TPMT*3B is a single-nucleotide substitution in exon 7 (coding-strand c.460G>A, plus-strand C>T at chr6:18138997 because TPMT is on the minus strand) that changes alanine 154 to threonine (p.Ala154Thr), in a region critical for substrate binding and protein stability. On its own, the 3B substitution moderately reduces enzyme activity by destabilising the folded protein. What makes *3B clinically important is that it is almost always inherited together with *3C (p.Tyr240Cys) on the same chromosome — a configuration called **TPMT*3A*. The two amino acid changes together accelerate proteolysis of the enzyme²² accelerate proteolysis of the enzyme
Tai et al. PNAS 1997 showed TPMT*3A protein has a half-life roughly 15-fold shorter than wild-type, with near-complete degradation via the ubiquitin-proteasome pathway, leaving carriers with essentially no functional TPMT from the *3A allele. When TPMT cannot methylate thiopurine drugs, these medications are diverted almost entirely into pathways that generate toxic thioguanine nucleotides (TGNs), which incorporate into DNA and cause cytotoxicity — normally kept in check by TPMT methylation to the inactive 6-methylmercaptopurine metabolite — producing profound myelosuppression.

The Evidence

TPMT is one of the oldest and best-documented pharmacogenes. The CPIC guideline for thiopurine dosing³³ CPIC guideline for thiopurine dosing
Clinical Pharmacogenetics Implementation Consortium — Level A evidence, the highest tier for clinical implementation was first published in 2011 and has been updated multiple times since, recommending pre-treatment TPMT genotyping for all patients starting azathioprine, 6-mercaptopurine, or thioguanine. The original 2011 CPIC guideline⁴⁴ original 2011 CPIC guideline
Relling MV et al. Clin Pharmacol Ther 2011 named TPMT*2, *3A, *3B, and *3C as the four clinically relevant no-function alleles, and the 2018 update⁵⁵ 2018 update
Relling MV et al. Clin Pharmacol Ther 2019 extended the framework to NUDT15. The original molecular characterisation of TPMT*3A/*3B/*3C by Otterness et al.⁶⁶ Otterness et al.
Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther 1997 found TPMT*3A (the *3B + *3C cis haplotype) in roughly 3.2-5.7% of Caucasian populations and in over 80% of Caucasian patients with deficient TPMT activity. A more recent genome-wide association study of TPMT enzyme activity⁷⁷ genome-wide association study of TPMT enzyme activity
Liu et al. Genomewide approach validates thiopurine methyltransferase activity as a monogenic pharmacogenomic trait. Clin Pharmacol Ther 2017 in 1,026 leukemia patients confirmed rs1800460 and rs1142345 as the two SNPs reaching genome-wide significance for TPMT activity, with TPMT being the only gene to reach that threshold. The FDA includes TPMT status in its pharmacogenomic biomarker table⁸⁸ pharmacogenomic biomarker table for azathioprine, mercaptopurine, and thioguanine, and the package inserts explicitly recommend genotyping or phenotyping before treatment.

Practical Implications

If you carry one or two copies of TPMT*3B, you are at risk for severe thiopurine-induced bone marrow suppression at standard doses. European populations carry the *3B variant at roughly 3.6% allele frequency, meaning about 7% of Europeans are heterozygotes (one functional TPMT allele) and roughly 1 in 800 are homozygous for *3B or compound heterozygous with another TPMT variant. The CPIC 2025 guideline recommends starting at 30-80% of the standard dose for intermediate metabolizers (one variant copy) and 10% of the standard dose or an alternative medication for poor metabolizers (two variant copies). Because TPMT deficiency classification depends on all variant alleles in combination, anyone with a *3B variant should also be checked for TPMT*3C, TPMT*2, and NUDT15 variants — especially if they have East Asian or admixed ancestry where NUDT15 is the dominant thiopurine safety gene.

Interactions

The dominant interaction for TPMT*3B is cis-haplotype configuration with TPMT*3C (rs1142345). In the overwhelming majority of Caucasian carriers, *3B and *3C are found on the same chromosome, forming the TPMT*3A haplotype⁹⁹ TPMT*3A haplotype
Otterness et al. found *3A accounted for ~84% of variant alleles in deficient Caucasians; *3B alone and *3C alone are each rare in isolation in this population. If your genome file shows you carry both rs1800460(T) and rs1142345(C), you most likely have TPMT*3A (both variants in cis on one chromosome) rather than two independent decreased-function alleles in trans. Clinical labs distinguish these configurations through phase determination, which requires long-read sequencing, family studies, or extended phenotyping — most SNP-array platforms cannot resolve cis vs trans without additional testing. This matters because *3A in cis behaves as a single deficient allele (heterozygote phenotype when one chromosome carries both variants), whereas *3B and *3C in trans (on separate chromosomes) would behave as compound heterozygous — two functional-null alleles — and produce the rare, severe poor-metabolizer phenotype.

A second critical interaction is with NUDT15 (rs116855232), the other thiopurine safety gene. NUDT15 loss-of-function variants are common in East Asian populations and act on a downstream step of thiopurine metabolism. Individuals carrying variants in both TPMT and NUDT15 require larger dose reductions than predicted by either gene alone, and both should be checked before thiopurine prescription. Finally, co-administration of allopurinol¹⁰¹⁰ allopurinol
Xanthine oxidase inhibitor used for gout; blocks an alternate thiopurine inactivation pathway or febuxostat with thiopurines creates a double-blockade that is particularly dangerous in TPMT variant carriers — the FDA label instructs reducing azathioprine to 25% of the standard dose when combined with allopurinol, and that reduction must be applied on top of any TPMT-based dose reduction.

The ADRB1 gene encodes the beta-1 adrenergic receptor¹¹ beta-1 adrenergic receptor
The primary receptor on cardiac muscle cells that binds adrenaline and noradrenaline, controlling heart rate, contractile force, and cardiac output in response to stress and exercise, the principal mediator of sympathetic nervous system control over the heart. When adrenaline and noradrenaline flood the bloodstream during exercise, stress, or danger, they bind this receptor and accelerate the heart. The Arg389Gly variant determines just how powerfully that signal is received.

At codon 389, most people carry the C allele (Arg389), which produces a receptor with higher basal coupling efficiency and stronger response to catecholamines. About 54% of Europeans are homozygous for this high-activity form; only 7% carry two copies of the reference G allele (Gly389). This makes Arg389 simultaneously the "variant" allele in name and the dominant allele in practice. The variant's importance lies not in rarity but in its influence on exercise heart rate response, beta-blocker pharmacogenomics, and myocardial infarction risk.

The Mechanism

At position 389 in the intracellular C-terminal tail of the receptor, the amino acid change from glycine (G allele) to arginine (C allele) alters the geometry of the region that couples to Gs protein²² Gs protein
The stimulatory G-protein that activates adenylyl cyclase when bound by a ligand-occupied receptor, generating cAMP as the intracellular second messenger. The Arg389 form has enhanced basal cAMP³³ cAMP
Cyclic adenosine monophosphate — the intracellular messenger that triggers protein kinase A activity, ultimately increasing heart rate and contractile force production even without catecholamine stimulation, and generates a larger cAMP surge when adrenaline binds compared to the Gly389 form.

This is not merely a quantitative difference. A 2008 cardiac gene expression study⁴⁴ 2008 cardiac gene expression study
Swift SM et al. Differential coupling of Arg- and Gly389 polymorphic forms of the beta1-adrenergic receptor leads to pathogenic cardiac gene regulatory programs. Physiol Genomics, 2008 using human heart tissue found that Arg389 receptor activation uniquely upregulates genes involved in inflammation, programmed cell death, and extracellular matrix remodeling — signaling programs not activated by the Gly389 form. This divergence in downstream gene regulation may explain why the genotype predicts differential cardiovascular outcomes and drug responses.

The Evidence

Exercise Heart Rate Response: The pharmacogenomic signature of this variant is most directly demonstrated in exercise contexts. A controlled study of 27 healthy adults⁵⁵ controlled study of 27 healthy adults
Muszkat M et al. The common Arg389gly ADRB1 polymorphism affects heart rate response to the ultra-short-acting β(1) adrenergic receptor antagonist esmolol in healthy individuals. Pharmacogenet Genomics, 2013 administered intravenous esmolol (an ultra-short-acting beta-1 blocker) during exercise. The inhibition of exercise-induced heart rate increase was 0.78 bpm in Gly389 homozygotes, 5.11 bpm in heterozygotes, and 10.22 bpm in Arg389 homozygotes — a 13-fold difference (p = 0.014). This dose-dependent genotype effect confirms that Arg389 carriers have a stronger adrenergic drive on exercise heart rate, and a correspondingly stronger response to blockade.

A study of 35 healthy subjects⁶⁶ study of 35 healthy subjects
Yogev D et al. Effects of sex and the common ADRB1 389 genetic polymorphism on the hemodynamic response to dobutamine. Pharmacogenet Genomics, 2015 using dobutamine infusion (a synthetic catecholamine) found that Arg389Arg homozygotes showed a 4.7-fold greater resting heart rate increase (12.95 vs 2.75 bpm) and a 3.9-fold greater renin response than Gly389Gly individuals. Heterozygotes showed intermediate responses. Genotype was the primary determinant in multivariate analysis (p = 0.011).

Beta-Blocker Response in Heart Failure: The most clinically impactful finding concerns beta-blocker dose optimization in heart failure. A pooled analysis of the BEST and HF-ACTION trials⁷⁷ pooled analysis of the BEST and HF-ACTION trials
Parikh KS et al. Dose Response of β-Blockers in Adrenergic Receptor Polymorphism Genotypes. Circ Genom Precis Med, 2018 (combined N = 1,997 patients) found that Arg389Arg homozygotes on high-dose beta-blocker therapy had a 60% reduction in all-cause mortality (HR 0.40, p = 0.002), compared to no significant benefit in Gly allele carriers (p > 0.2). Critically, at low doses, Arg389Arg individuals actually showed increased mortality (HR 1.83, p = 0.015) — suggesting that underdosing may be harmful in this genotype. A 2022 pharmacogenomics study⁸⁸ 2022 pharmacogenomics study
Guerra LA et al. Genetic polymorphisms in ADRB2 and ADRB1 are associated with differential survival in heart failure patients taking β-blockers. Pharmacogenomics J, 2022 confirmed this interaction: Arg389 carriers derived greater survival benefit at higher beta-blocker doses (p_interaction = 0.043).

Acute MI and Cardioprotection: In a Japanese case-control study⁹⁹ Japanese case-control study
Iwai C et al. Arg389Gly polymorphism of the human beta1-adrenergic receptor in patients with nonfatal acute myocardial infarction. Am Heart J, 2003 of 354 AMI patients versus 354 matched controls, Arg389 homozygotes had an odds ratio of 2.86 (95% CI 1.92–4.26, p = 0.0001) for nonfatal MI, independent of classical risk factors. This risk likely reflects the enhanced sympathetic activation of the Arg389 receptor, which can drive adverse myocardial remodeling. Consistent with this, a 2025 clinical trial analysis¹⁰¹⁰ 2025 clinical trial analysis
Clemente-Moragón A et al. Pharmacogenomics and chronotherapy of drug-induced cardioprotection in acute myocardial infarction. Nat Commun, 2025 found that metoprolol reduced infarct size exclusively in Arg389 homozygotes; Gly389 carriers received no cardioprotective benefit, with in-silico modeling showing unstable metoprolol binding to the Gly389 variant.

Blood Pressure Response: A Chinese study of 87 hypertensives¹¹¹¹ Chinese study of 87 hypertensives
Si D et al. Association of common polymorphisms in β1-adrenergic receptor with antihypertensive response to carvedilol. J Cardiovasc Pharmacol, 2014 found that Arg389 homozygotes had a 4-fold greater diastolic blood pressure reduction on carvedilol (10.61 vs 2.62 mmHg, p = 0.013), suggesting that genotype-guided prescribing could optimize antihypertensive therapy.

Practical Implications

For Arg389Arg (CC) individuals: your beta-1 receptors have higher basal activity and generate a stronger heart rate and blood pressure response to sympathetic stimulation. In heart failure or post-MI contexts, high-dose beta-blocker therapy is particularly important and effective for you. Inform your cardiologist of this genotype if you have cardiovascular disease.

For Gly389Gly (GG) individuals: your receptors have lower basal coupling efficiency, resulting in blunted catecholamine response. Beta-blocker response is weaker and may not confer the same survival benefits in heart failure. In acute MI, metoprolol-based cardioprotection may not apply to your genotype.

For heterozygotes (CG): your response profile is intermediate, tracking dose-dependently with the number of Arg389 alleles.

Interactions

ADRB1 Arg389Gly interacts with the ADRB1 Ser49Gly variant (rs1801252) to form functionally distinct haplotypes. The Ser49/Arg389 haplotype (the more active combination) has been associated with greater beta-blocker benefit in several studies. Petersen et al. (2011) found that Arg389 homozygotes combined with the ADRB2 Gln27 (rs1042714) variant had doubled mortality on carvedilol but not on metoprolol, suggesting that beta-blocker choice may matter when multiple adrenergic receptor variants are present.

The CLOCK gene (Circadian Locomotor Output Cycles Kaput) encodes the master transcription factor¹¹ transcription factor
A protein that binds to DNA and activates the expression of other genes, in this case driving the ~24-hour circadian rhythm at the heart of the mammalian circadian clock. Working with its partner BMAL1, the CLOCK protein drives rhythmic expression of thousands of genes that govern sleep-wake cycles, hormone secretion, metabolism, and body temperature. The rs1801260 variant — commonly called 3111T>C using the coding strand notation — sits in the 3' untranslated region (3'UTR)²² 3' untranslated region (3'UTR)
The section of mRNA after the stop codon that doesn't code for protein but regulates mRNA stability, localization, and translation efficiency of CLOCK mRNA, where it affects how long the messenger RNA persists in the cell before being degraded.

This was the first human clock gene polymorphism linked to chronotype, identified in a landmark 1998 study³³ landmark 1998 study
Katzenberg D et al. A CLOCK polymorphism associated with human diurnal preference. Sleep, 1998 at Stanford. Carriers of the minor allele scored significantly lower on the Horne-Ostberg morningness-eveningness questionnaire, indicating a shift toward evening preference that was independent of age, sex, and ethnicity.

The Mechanism

The rs1801260 variant falls within a miR-182 binding site⁴⁴ miR-182 binding site
MicroRNA-182 binds to the 3'UTR of CLOCK mRNA and promotes its degradation; the variant allele disrupts this binding in the CLOCK 3'UTR. The minor allele (G on plus strand, C in coding strand notation) disrupts this microRNA interaction site, resulting in increased CLOCK mRNA stability. Cell-based studies using mouse embryonic fibroblasts transfected with the rs1801260 construct showed that the variant allele produces significantly higher levels of CLOCK and downstream Per2 mRNA.

Higher CLOCK protein levels extend the active phase of the transcription-translation feedback loop⁵⁵ transcription-translation feedback loop
The core circadian mechanism: CLOCK/BMAL1 activate PER and CRY genes, whose proteins then inhibit CLOCK/BMAL1, creating a ~24-hour oscillation that defines circadian period length. This molecular shift manifests behaviorally as delayed sleep onset, higher evening activity, and a preference for later bed and wake times.

The Evidence

The original Katzenberg study⁶⁶ original Katzenberg study
Katzenberg D et al. A CLOCK polymorphism associated with human diurnal preference. Sleep, 1998 genotyped 410 adults from a population-based sample and found that C allele carriers had significantly lower Horne-Ostberg scores (shifted toward eveningness), independent of age, sex, and ethnic background.

Benedetti et al. (2007)⁷⁷ Benedetti et al. (2007)
Benedetti F et al. Actimetric evidence that CLOCK 3111 T/C SNP influences sleep and activity patterns in patients affected by bipolar depression. Am J Med Genet B Neuropsychiatr Genet, 2007 provided objective actimetric data in 39 bipolar depressed inpatients, showing that C allele carriers had 79 minutes later sleep onset and 75 fewer minutes of total sleep compared to T/T homozygotes, with higher evening activity levels — all despite similar depression severity.

The metabolic consequences of this chronotype shift have been well documented. Garaulet et al. (2010)⁸⁸ Garaulet et al. (2010)
Garaulet M et al. CLOCK gene is implicated in weight reduction in obese patients participating in a dietary programme based on the Mediterranean diet. Int J Obes, 2010 studied 1,100 overweight and obese subjects and found that minor allele carriers lost significantly less weight during a Mediterranean diet intervention (P = 0.008), with more carriers being short sleepers (59% vs 41%, P < 0.05).

Garcia-Rios et al. (2014)⁹⁹ Garcia-Rios et al. (2014)
Garcia-Rios A et al. Beneficial effect of CLOCK gene polymorphism rs1801260 in combination with low-fat diet on insulin metabolism in metabolic syndrome. Chronobiol Int, 2014 found significant gene-diet interactions in 475 metabolic syndrome patients: after 12 months on a low-fat diet, major allele homozygotes (AA) showed lower insulin and HOMA-IR, while minor allele carriers did not improve as much (interaction P = 0.009 for insulin, P = 0.014 for HOMA-IR).

An association with adult ADHD¹⁰¹⁰ association with adult ADHD
Kissling C et al. A polymorphism at the 3'-untranslated region of the CLOCK gene is associated with adult attention-deficit hyperactivity disorder. Am J Med Genet B, 2008 was found in 143 subjects (P < 0.001), consistent with the known circadian rhythm disruption in ADHD.

It is important to note that large genome-wide association studies of chronotype have not consistently replicated the rs1801260 signal. This may reflect the modest effect size of any single variant and the polygenic nature of chronotype, where hundreds of variants each contribute small effects.

Practical Implications

The CLOCK 3111C allele is not a sleep disorder — it is a common variant that tilts circadian preference toward eveningness. The practical relevance is in recognizing this tendency and structuring daily routines to work with it rather than against it.

For weight management, the evidence suggests that minor allele carriers may benefit from paying particular attention to meal timing, eating the main meal earlier in the day, and avoiding late-night eating. The combination of evening preference and shorter sleep creates a metabolic environment that favors weight gain through altered ghrelin, GLP-1, and insulin dynamics.

Light exposure is the strongest environmental cue for circadian entrainment. Morning bright light exposure (10,000 lux for 20-30 minutes upon waking) can help shift the circadian phase earlier, partially counteracting the genetic evening tendency. Conversely, evening blue light from screens further delays sleep onset in already evening-shifted individuals.

Interactions

The CLOCK 3111C allele interacts with SIRT1 variants to produce additive effects on evening preference and weight loss resistance. Garaulet et al. (2012) showed that carriers of minor alleles at both SIRT1 (rs1467568) and CLOCK (rs1801260) had the strongest evening preference and greatest resistance to weight loss in a behavioral obesity treatment.

CLOCK also interacts functionally with PER2 and PER3 — the period genes that form the negative limb of the circadian feedback loop. While specific gene-gene interaction studies for rs1801260 with PER variants are limited, the biological pathway logic is strong: increased CLOCK expression drives higher PER/CRY production, and variants in PER genes that alter this response could compound the circadian shift.

Atherosclerosis has long been recognized as more than a simple plumbing problem — it is fundamentally an inflammatory disease. At its center sits Toll-Like Receptor 4 (TLR4)¹¹ Toll-Like Receptor 4 (TLR4)
a pattern recognition receptor on the surface of immune cells and vascular endothelium that detects lipopolysaccharide (LPS) from Gram-negative bacteria and endogenous danger signals such as oxidized LDL. When TLR4 fires, it triggers NF-κB signaling and a cascade of pro-inflammatory cytokines — TNF-α, IL-6, IL-1β — that drive plaque formation and destabilization. rs1927911 is an intronic variant in TLR4 that acts as a tag SNP for haplotype variation across the gene, with the A allele (reported as T in chip notation) associated with modestly attenuated TLR4-driven vascular inflammation.

The Mechanism

TLR4 sits on chromosome 9q32-q33 and is expressed on monocytes, macrophages, dendritic cells, vascular endothelial cells, and smooth muscle cells. Upon detecting LPS or endogenous ligands (heat shock proteins, oxidized phospholipids, fibronectin), TLR4 dimerizes, recruits MyD88 and TRIF adaptor proteins²² MyD88 and TRIF adaptor proteins
intracellular signaling scaffolds that relay TLR4 activation to downstream kinase cascades, and activates NF-κB. The result: transcription of pro-inflammatory genes in the arterial wall that promote foam cell formation, smooth muscle proliferation, and plaque instability. rs1927911 lies in intron 1 and is thought to tag regulatory variation that modulates TLR4 expression or splicing in vascular tissues, rather than altering the receptor's LPS-binding domain directly. Carriers of two G alleles may have somewhat higher TLR4-mediated inflammatory tone in the vessel wall.

The Evidence

The cardiovascular link was established through several lines of evidence:

Enquobahrie et al. 2008³³ Enquobahrie et al. 2008
Cholesterol Ester Transfer Protein, Interleukin-8, PPARA, and Toll-like Receptor 4 Genetic Variations and Risk of Incident Nonfatal Myocardial Infarction and Ischemic Stroke. Am J Cardiol, 2008 studied 848 MI cases and 2,682 controls drawn from postmenopausal women and hypertensive men and women. They found the rs1927911 A allele (reported as T in chip notation) associated with a lower risk of nonfatal MI (OR 0.88, 95% CI 0.77–0.99), consistent with reduced TLR4-mediated vascular inflammation.

A 2017 systematic review and meta-analysis⁴⁴ 2017 systematic review and meta-analysis
Xie et al. Roles of TLR Gene Polymorphisms in Atherosclerosis. Scand J Immunol of 35,317 subjects across 40 studies found that TLR4 rs1927911 was significantly associated with cerebral infarction in the recessive model (OR 0.67, 95% CI 0.46–0.96, P=0.03), suggesting AA homozygotes have meaningfully lower cerebral infarction risk compared to GG+AG individuals.

An earlier Song et al. 2015⁵⁵ Song et al. 2015
TLR4 rs1927911, but Not TLR2 rs5743708, Is Associated With Atherosclerotic Cerebral Infarction in the Southern Han Population. Medicine 94:e381 case-control study (170 ACI patients, 149 controls) found genotype and allele frequencies significantly differed between ACI patients and healthy controls, nominating rs1927911 as a risk factor for atherosclerotic cerebral infarction. Critically, this effect was independent of blood pressure, fasting blood glucose, and serum lipids — pointing to an inflammatory mechanism rather than metabolic mediation.

Mechanistic support comes from the landmark Kiechl et al. 2002 NEJM⁶⁶ Kiechl et al. 2002 NEJM
Toll-Like Receptor 4 Polymorphisms and Atherogenesis study establishing that TLR4 signaling attenuation (via the coding Asp299Gly variant) reduces carotid atherosclerosis progression, validating the TLR4 pathway as genuinely causal in human atherogenesis rather than merely correlative.

Evidence is moderate — population studies are replication-level but effect sizes are modest (OR ~0.88 for MI), and the intronic rs1927911 does not have a confirmed functional mechanism of its own; it acts as a proxy for TLR4 haplotype variation.

Practical Actions

For GG genotype carriers, the actionable implication is to reduce the endogenous ligands that activate TLR4 in the vessel wall. Saturated fatty acids — particularly palmitic acid from palm oil, lard, and heavily processed meats — are endogenous TLR4 agonists that trigger vascular inflammation independent of LPS. Substituting with omega-3-rich fats (EPA/DHA) antagonizes TLR4 signaling through FFAR4/GPR120 and reduces downstream NF-κB activation. Periodontal disease is a major source of systemic LPS from Gram-negative oral bacteria; treatment of periodontal inflammation demonstrably reduces systemic inflammatory markers including hsCRP.

Monitoring high-sensitivity CRP (hsCRP) provides a direct readout of the low-grade vascular inflammation that TLR4-pathway variation influences. A value consistently above 2.0 mg/L in a person with a GG genotype and no obvious infection or injury source warrants deeper evaluation for periodontal disease, subclinical infection, and dietary saturated fat load.

Interactions

rs1927911 tags haplotype variation in the TLR4 gene and should be interpreted alongside the coding variants rs4986790 (Asp299Gly) and rs4986791 (Thr399Ile), which directly alter the receptor's extracellular domain and have their own independent evidence for cardiovascular associations. The A20/TNFAIP3 protein (encoded by the TNFAIP3 gene, rs2230926) terminates NF-κB signaling downstream of TLR4; individuals with both high TLR4 inflammatory tone and reduced A20 braking capacity may have amplified vascular inflammatory responses. The NOS2 pathway (rs2779249) is also downstream of NF-κB activation and may compound effects in those with multiple pro-inflammatory genotypes.

Of all the genetic pathways linked to longevity, the insulin/IGF-1 signaling (IIS) pathway¹¹ insulin/IGF-1 signaling (IIS) pathway
The IIS pathway coordinates growth, metabolism, and stress response across almost all animals. When signaling is reduced, cells shift from growth mode into maintenance and repair mode, which appears to extend lifespan in every organism tested from yeast to primates is the most replicated. This variant in IGF1R — the gene encoding the insulin-like growth factor 1 receptor — sits at the very hub of that pathway. It is a synonymous variant, meaning the DNA change does not alter the protein sequence. Yet despite this "silent" appearance, carriers of the A allele consistently show lower circulating IGF-1 levels and are overrepresented among people who live the longest.

The Mechanism

The variant is a G-to-A change at position 3179 of the IGF1R coding sequence, within exon 16. Both the G and A versions of codon 1013 encode the same amino acid (glutamic acid), which is why this is classified as synonymous. So why does it matter?

Synonymous mutations can powerfully affect gene function²² Synonymous mutations can powerfully affect gene function
So-called "silent" mutations can alter mRNA secondary structure, disrupt exonic splicing enhancers or silencers, change codon usage (affecting translation speed and protein folding), and alter mRNA stability — none of which are detectable at the amino acid level through several mechanisms not visible at the protein level. For rs2229765, the predominant hypothesis is that the G-to-A change disrupts an exonic splicing enhancer³³ exonic splicing enhancer
ESEs are short sequences within exons recognized by SR proteins. They promote inclusion of the surrounding exon in the final mRNA. Disrupting an ESE can cause exon skipping, leading to a shorter, sometimes less functional receptor protein, shifting the balance of IGF1R mRNA splice isoforms. The result appears to be subtly reduced functional receptor at the cell surface, which in turn leads to lower circulating free IGF-1 (since IGF-1 in the bloodstream is partly regulated by its receptor's clearance and feedback activity).

The Evidence

The foundational human study came from Bonafe et al. in 2003⁴⁴ Bonafe et al. in 2003
Bonafe M et al. Polymorphic variants of insulin-like growth factor I (IGF-I) receptor and phosphoinositide 3-kinase genes affect IGF-I plasma levels and human longevity. J Clin Endocrinol Metab, 2003. In an Italian population study comparing 278 young-to-middle-aged adults (17-85 years) with 218 very long-lived individuals (86-109 years), carriers of the A allele had lower free plasma IGF-1 levels and were significantly more common among the oldest group.

The TRELONG (Treviso Longeva) study confirmed and extended this in a larger, longitudinal Italian cohort of 668 subjects aged 70-106. Albani et al. 2009⁵⁵ Albani et al. 2009
Albani D et al. A polymorphic variant of the insulin-like growth factor 1 (IGF-1) receptor correlates with male longevity in the Italian population. BMC Geriatrics, 2009 found a sex-specific pattern: in men, the A allele frequency increased from 34.4% in the 70-85 age group to 43.7% among those 85 and older (p=0.04). Men with the AA genotype had the lowest IGF-1 levels in the oldest cohort (mean 119 ± 50 ng/mL, versus 185 ± 74 ng/mL in GG men). A subsequent prospective follow-up of this cohort Albani et al. 2011⁶⁶ Albani et al. 2011
Albani D et al. Insulin-like growth factor 1 receptor polymorphism rs2229765 and circulating interleukin-6 level affect male longevity in a population-based prospective study. Aging Male, 2011 found that AA males had a 76% reduced mortality risk compared to GG males (OR 0.24, 95% CI 0.07-0.64, p=0.008). The effect was not replicated in women, suggesting sex-specific biology in IIS pathway regulation of aging.

A gene combination study Barbieri et al. 2012⁷⁷ Barbieri et al. 2012
Barbieri M et al. A/Asp/Val allele combination of IGF1R, IRS2, and UCP2 genes is associated with better metabolic profile, preserved energy expenditure parameters, and low mortality rate in longevity. Age (Dordr), 2012 found that the A allele of IGF1R combined with specific variants in IRS2 (Asp allele) and UCP2 (Val allele) was associated with a 3.2-fold increased probability of reaching extreme old age (OR 3.185, 95% CI 1.63-6.19, p=0.0006) in 722 Italian subjects. This combination was also associated with lower insulin resistance, preserved resting metabolic rate, and better energy expenditure parameters.

A meta-analysis of four studies⁸⁸ meta-analysis of four studies
Di Bona D et al. Association between genetic variations in the insulin/insulin-like growth factor (IGF-1) signaling pathway and longevity: a systematic review and meta-analysis. Curr Vasc Pharmacol, 2014 found that across available data, subjects carrying the A allele of rs2229765 had a significantly greater probability of longevity. Evidence level is moderate: findings are replicated across multiple Italian cohorts, but populations studied are geographically limited and sex-specific effects complicate interpretation.

Practical Implications

This variant acts through reduced IIS signaling. The same pathway is modified by protein intake (protein directly raises IGF-1 levels), periodic fasting, and dietary patterns. Carriers of the A allele who wish to leverage the IGF-1-lowering benefit that appears genetically advantageous can amplify it through targeted dietary choices — primarily moderating protein intake during midlife. The key evidence base here comes from studies showing protein restriction substantially reduces IGF-1 in humans, with most longevity benefit concentrated in the 50-65 age range for moderate protein reduction.

Monitoring serum IGF-1 allows calibration of diet and lifestyle interventions. Total IGF-1 of 100-175 ng/mL in adults is generally associated with the longevity range, while levels above 200 ng/mL have been linked to increased cancer risk in multiple epidemiological studies.

Interactions

The strongest documented interaction is with IRS2 (rs1805097, the Asp/Gly variant) and UCP2 (rs659366, the Val/Ala variant). When all three genes carry their "longevity" alleles (IGF1R-A, IRS2-Asp, UCP2-Val), the longevity association is dramatically amplified (OR 3.185 vs ~1.3 for any single variant alone). This reflects the IIS pathway's interconnected nature: IGF1R sits upstream, IRS2 is the intracellular docking protein it signals through, and UCP2 modulates the mitochondrial energy dissipation that determines how cells respond to reduced IIS signaling. Variants in PI3K pathway genes that work downstream of IGF1R may further modify this effect.

IGF-1 levels are also influenced by variants in the IGF1 gene itself (particularly rs35767 in the promoter region, which affects IGF-1 transcription). Carrying the IGF1R A allele alongside IGF1 promoter variants that reduce IGF-1 production could compound the IIS reduction further.

Your body cannot manufacture high-density lipoprotein particles from scratch — it has to build them one lipid at a time. The key enzyme driving that process is ABCA1¹¹ ABCA1
ATP-binding cassette transporter A1, a membrane protein that pumps cholesterol and phospholipids out of cells onto apolipoprotein A-I scaffolds. rs2249891 sits in the fourth intron of the ABCA1 gene and is one of several common variants at this locus that have been linked to variation in HDL-C levels. ABCA1 is among the most replicated lipid GWAS loci in human genetics.

The Mechanism

ABCA1 catalyzes the rate-controlling step in reverse cholesterol transport²² reverse cholesterol transport
the pathway by which peripheral tissues off-load excess cholesterol back to the liver for excretion — the transfer of cellular cholesterol and phospholipids to lipid-poor apolipoprotein A-I (apoA-I). This lipidation event creates nascent HDL particles, which mature as they circulate and pick up additional lipids from other transporters (ABCG1, SR-BI). The rs2249891 variant is intronic (c.422-161T>C on the coding strand, which corresponds to A>G on the genomic plus strand) and does not alter the ABCA1 protein directly. It likely acts as a tag for functional regulatory variation nearby, or contributes through subtle effects on splicing efficiency or transcriptional regulation that reduce ABCA1 expression in relevant tissues such as the liver and macrophages.

When ABCA1 activity is reduced — whether by coding mutations (Tangier disease) or by common regulatory variants — cholesterol efflux from macrophages in arterial walls is impaired. Lipid-laden macrophages become foam cells, the building blocks of atherosclerotic plaques.

The Evidence

The ABCA1 locus has been implicated in HDL-C levels since early GWAS work. Willer et al.³³ Willer et al.
Willer CJ et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet, 2008 confirmed ABCA1 among eleven established lipid loci in a genome-wide scan of ~20,000 individuals. The specific variant rs2249891 was identified by Peloso et al.⁴⁴ Peloso et al.
Peloso GM et al. Common genetic variation in multiple metabolic pathways influences susceptibility to low HDL-cholesterol and coronary heart disease. J Lipid Res, 2010 in a candidate-gene study of 60 key HDL-metabolism genes across 699 cases (low HDL-C plus coronary heart disease, from the VA-HIT trial) and 705 controls (Framingham Offspring Study). The G allele showed significant association with case status after adjustment for multiple testing within the gene (P = 0.0126).

Importantly, a comprehensive review⁵⁵ comprehensive review
Frikke-Schmidt R. Genetic variation in the ABCA1 gene, HDL cholesterol, and risk of ischemic heart disease. Atherosclerosis, 2010 established that both common and rare ABCA1 variants contribute to HDL-C levels and ischemic heart disease risk in the general population, but that the cardiovascular risk associated with ABCA1 variants appears to be partly independent of measured HDL-C levels. This suggests ABCA1 affects vascular biology through mechanisms beyond simply lowering circulating HDL — including macrophage cholesterol efflux capacity, which is not fully captured by serum HDL-C measurements.

Practical Actions

Carriers of the G allele — particularly GG homozygotes — have somewhat lower expected HDL-C levels based on genetic predisposition. Two lifestyle factors have specific documented interactions with ABCA1 genotype. Nishida et al.⁶⁶ Nishida et al.
Nishida Y et al. The interaction between ABCA1 polymorphism and physical activity on HDL-cholesterol levels. J Lipid Res, 2020 found that the HDL-raising benefit of carrying a favorable ABCA1 allele was attenuated in physically inactive men — a gene-by-activity interaction suggesting that ABCA1-variant carriers who maintain aerobic fitness preserve more of their HDL-generating capacity. Dietary fat composition also matters: ABCA1 expression is regulated by liver X receptor (LXR), which is activated by oxysterols from cholesterol metabolism. Diets high in refined carbohydrates and trans fats suppress LXR-ABCA1 signaling, while unsaturated fats and plant sterols may modestly upregulate it.

Monitoring HDL-C at least annually is warranted for G allele carriers, as genetically low HDL may not trigger clinical concern on a single test but predicts sustained cardiovascular risk over time. Cholesterol efflux capacity — a measure of how effectively cells clear cholesterol — is not routinely measured but is the most direct readout of ABCA1 function; ask a cardiologist about functional lipid testing if standard panels are consistently borderline.

Interactions

rs2249891 sits at a locus that is in partial linkage disequilibrium with other ABCA1 variants, including rs1883025 (an extensively studied intronic variant with documented interactions with physical activity on HDL-C) and rs2575875 (an intronic enhancer variant with allele-specific regulatory activity in liver cells identified by Howard et al. 2019, PMID 31039173). Individuals carrying multiple ABCA1 variants with consistent directional effects on HDL regulation may have a compounded reduction in cholesterol efflux capacity compared to single-variant carriers.

Chromosome 6q27 hosts one of the most consistently replicated autoimmune susceptibility loci in the human genome. The region — spanning RNASET2, FGFR1OP (also called CEP43), and CCR6 — has been independently confirmed in genome-wide association studies for Crohn's disease¹¹ Crohn's disease
A form of inflammatory bowel disease causing transmural inflammation anywhere in the gastrointestinal tract, ulcerative colitis, rheumatoid arthritis, vitiligo, and autoimmune thyroid disease. The rs2301436 variant sits within an intron of FGFR1OP and is one of the anchor SNPs that tags the autoimmune risk signal at this locus. Because the locus spans three genes, the precise causal variant and primary effector gene have not been fully resolved, but functional evidence points strongly to nearby CCR6 as the biological driver.

The Mechanism

FGFR1OP (fibroblast growth factor receptor 1 oncogene partner; gene symbol CEP43) encodes a centrosomal scaffolding protein involved in microtubule anchoring and ciliogenesis. It is the fusion partner in 8p11 myeloproliferative syndrome, where a t(6;8) chromosomal translocation creates a CEP43-FGFR1 oncogene. However, rs2301436 is an intronic variant with MODIFIER-level predicted functional impact — its disease relevance almost certainly derives from linkage disequilibrium²² linkage disequilibrium
Correlated inheritance of nearby variants due to limited recombination between them; an intronic FGFR1OP SNP can tag regulatory variants in neighboring CCR6 because both are inherited together in the same chromosomal block with functionally important variants in the adjacent CCR6 gene.

CCR6 (C-C chemokine receptor 6, CD196) is expressed on immature dendritic cells and memory T cells, where it governs migration in response to its ligand CCL20/MIP-3α. In the intestine, the CCL20-CCR6 axis controls dendritic cell homing to Peyer's patches³³ Peyer's patches
Organized lymphoid follicles in the small intestine where immune surveillance of luminal contents occurs and regulates the balance between tolerogenic and inflammatory responses to gut bacteria. Dysregulation of this axis is a mechanistically plausible driver of both Crohn's disease and rheumatoid arthritis, two conditions where T-cell trafficking and mucosal immunity are central to pathogenesis. The variant rs3093024, in strong LD with rs2301436, has been identified as a regulatory CCR6 variant affecting gene expression in immune cells.

The Evidence

The strongest GWAS evidence for rs2301436 comes from two IBD studies. Barrett et al. 2008 in Nature Genetics⁴⁴ Barrett et al. 2008 in Nature Genetics
3,230 CD cases and 4,829 controls; replication in 3,664 cases and 7,532 controls; European populations mapped the RNASET2-FGFR1OP-CCR6 locus as one of more than 30 distinct Crohn's disease susceptibility loci, with rs2301436-T carrying an odds ratio of approximately 1.21 (p=1×10⁻¹²) — a robust, replicated association that has withstood numerous follow-up studies. The same locus was independently captured in McGovern et al. 2010⁵⁵ McGovern et al. 2010
2,693 UC cases and 6,791 controls; genome-wide significant for ulcerative colitis susceptibility, demonstrating that the autoimmune signal spans both major forms of IBD.

For rheumatoid arthritis, Stahl et al. 2010⁶⁶ Stahl et al. 2010
Meta-analysis of 5,539 RA cases and 20,169 controls; 7 new loci at genome-wide significance identified the CCR6 locus — overlapping with rs2301436 — among new RA susceptibility loci, establishing this region as a broad autoimmune risk locus not confined to IBD. A Korean Crohn's disease GWAS ⁷⁷ Yang et al. Gut 2014; 1,001 Korean CD cases and 4,304 controls further replicated the RNASET2-FGFR1OP-CCR6 signal in a non-European population, supporting its status as a cross-ancestry IBD susceptibility locus.

At the cellular level, a study of hematopoietic stem cell transplantation ⁸⁸ Broen et al. 2011; 180 matched-related transplant recipients found that CCR6 genotype at rs2301436 was associated with complications of immune reconstitution: donors homozygous for one allele showed markedly less chronic graft-versus- host disease, while the alternative homozygous genotype was associated with higher invasive fungal disease risk (OR 3.59, p=0.008) — a direct demonstration that this variant modulates clinically meaningful immune responses in vivo.

Practical Implications

Carrying the T allele at rs2301436 increases gut immune surveillance activity in ways that elevate Crohn's disease and IBD risk. The effect is additive — each T allele copy contributes independently to risk. Practically, T allele carriers benefit most from being alert to early IBD symptoms (prolonged diarrhea, abdominal cramping, blood in stool, unintended weight loss, perianal symptoms), pursuing prompt investigation rather than watchful waiting, and understanding that smoking is a particularly potent environmental trigger in people with genetic Crohn's susceptibility. Dietary choices that support the mucosal barrier and reduce luminal antigenic load may also be relevant, though specific dietary prescriptions for this genotype remain an area of active research.

Interactions

The strongest documented interaction at this locus involves other CCR6- pathway variants. rs3093024, a CCR6 promoter-region regulatory variant in LD with rs2301436, was identified in Kochi et al. 2010 (PMID 20453841) as the primary rheumatoid arthritis signal at this locus, with rs2301436 serving as a secondary tag. Carriers of the T allele at rs2301436 who also carry risk alleles in IBD-associated genes such as NOD2 (rs2066844, rs2066845, rs2066847), IL23R (rs11209026), or ATG16L1 (rs2241880) may experience compounding susceptibility to Crohn's disease, consistent with the polygenic architecture of IBD risk.

Most genetic risk factors influence one thing. NEGR1¹¹ NEGR1
Neuronal Growth Regulator 1 — a GPI-anchored cell adhesion molecule in the IgLON superfamily, expressed on the surface of neurons in the hypothalamus, hippocampus, and prefrontal cortex. GPI-anchored means the protein is tethered to the outer cell membrane by a lipid anchor rather than spanning it — placing NEGR1 at the neuron's outermost face where it mediates cell-to-cell contact influences two. Variants near this gene are among the most replicated findings in both the obesity and the major depression genetics literature — the same neurons that control appetite circuits in the hypothalamus also organize the monoaminergic signaling that underlies mood regulation.

Rs2568958 sits near a 45-kilobase deletion polymorphism upstream of NEGR1 that was first identified in 2009 as one of six new BMI loci²² six new BMI loci
Willer CJ et al. Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet, 2009 reaching genome-wide significance, and has since been independently confirmed in the depression GWAS literature as part of the same causal signal.

The Mechanism

NEGR1 belongs to the IgLON superfamily³³ IgLON superfamily
A family of immunoglobulin-domain cell adhesion molecules — LSAMP, OPCML, NRCAM, NEGR1, and HNT/NTROPHY — that guide axonal growth and synapse formation. They are expressed on the outer surface of neurons and regulate which neurons bond with which, effectively controlling the wiring diagram of the developing and adult brain. In the hypothalamus, NEGR1 guides the physical architecture of circuits that integrate energy status signals with behavioral outputs — it helps wire the neurons that receive leptin and insulin signals and translate them into satiety, mood, and energy expenditure.

The rs2568958 G allele disrupts NEGR1 expression through two mechanisms. First, it lies near a structural deletion⁴⁴ structural deletion
The Willer 2009 study identified a 45-kb deletion immediately upstream of NEGR1, perfectly tagged by the lead SNPs in this region (including rs2815752 and rs2568958). Deletion of this segment removes regulatory sequences that drive NEGR1 expression, particularly in hypothalamic neurons in the NEGR1 upstream region that removes regulatory sequences controlling hypothalamic expression. Second, eQTL analyses in the Levey et al. 2021⁵⁵ Levey et al. 2021
Levey DF et al. Bi-ancestral depression GWAS in the Million Veteran Program and meta-analysis in >1.2 million individuals. Nat Neurosci, 2021 dataset confirmed that the depression-risk allele at the NEGR1 locus acts as a brain eQTL: it statistically predicts lower NEGR1 mRNA abundance specifically in hypothalamic tissue. Less NEGR1 protein means less synaptic scaffolding in exactly the circuits that connect mood and appetite.

In animal models, NEGR1-deficient mice⁶⁶ NEGR1-deficient mice
Noh K et al. Negr1 controls adult hippocampal neurogenesis and affective behaviors. Mol Psychiatry, 2019 show severely impaired long-term potentiation in the hippocampal dentate gyrus, near-abolition of adult neurogenesis, and robust depression- and anxiety-like behaviors across validated assays. The mechanistic pathway proceeds through the LIFR–Lcn2 axis: NEGR1 activates the leukemia inhibitory factor receptor, which drives Lipocalin-2 production, which is itself required for hippocampal neurogenesis. Meanwhile, a 2022 study by Kaare et al.⁷⁷ Kaare et al.
Kaare M et al. Depression-Associated Negr1 Gene-Deficiency Induces Alterations in the Monoaminergic Neurotransmission. Brain Sciences, 2022 found dysregulated signaling across all three monoamine systems — elevated striatal dopamine release, altered hippocampal serotonin, and disrupted norepinephrine responses — confirming that NEGR1's role extends well beyond structural wiring into active neurotransmitter circuit organization.

The Evidence

The BMI evidence arrived first. In the landmark Willer et al. 2009⁸⁸ Willer et al. 2009
Willer CJ et al. Six new loci associated with body mass index. Nat Genet, 2009 meta-analysis of over 32,000 individuals, the NEGR1 locus reached genome-wide significance for BMI with an effect of approximately 0.05 SD units per allele (~0.36 kg/m²). Crucially, several of the identified loci — including NEGR1 — were expressed in the central nervous system, pointing to a neuronal rather than peripheral mechanism for their effect on body weight.

The depression evidence followed years later at far greater statistical power. The Howard et al. 2019⁹⁹ Howard et al. 2019
Howard DM et al. Genome-wide meta-analysis of depression identifies 102 independent variants. Nat Neurosci, 2019 study (N=807,553, including 246,363 cases) identified the NEGR1 locus at P=3.55×10⁻¹⁵ for major depression. This finding was further strengthened in the Levey et al. 2021¹⁰¹⁰ Levey et al. 2021
Levey DF et al. Bi-ancestral depression GWAS. Nat Neurosci, 2021 analysis (N=1,154,267) where the lead NEGR1 SNP reached P=8.9×10⁻²⁹ — one of the highest-confidence depression loci in the human genome.

The shared genetic signal was formally characterized by Zhang et al. 2024¹¹¹¹ Zhang et al. 2024
Zhang H et al. Dissecting shared genetic architecture between depression and body mass index. BMC Medicine, 2024: depression and BMI share a genetic correlation of rg=0.19 (P=4×10⁻²⁶), and among all shared loci, NEGR1 was the single most significant gene. Brain tissue from individuals with both depression and obesity showed the greatest reductions in NEGR1 expression, concentrated in the nucleus accumbens and anterior cingulate cortex — reward and emotional valuation centers.

Replication of rs2568958 specifically extends to African-American populations: Hester et al. 2011¹²¹² Hester et al. 2011
Hester JM et al. Implication of European-derived adiposity loci in African Americans. PLoS Genet, 2011 confirmed the rs2568958-BMI association (P<0.05) across six African-American cohorts (N=4,992), with effect sizes of 0.04–0.06 SD units per allele — demonstrating this is not a European-specific finding.

Practical Implications

For G-allele carriers, the actionable insight sits at the intersection of the two pathways NEGR1 organizes: hippocampal neurogenesis and hypothalamic monoamine architecture. Aerobic exercise is the most potent behavioral driver of BDNF-mediated hippocampal neurogenesis — directly compensating for reduced LIFR-Lcn2 signaling. Dietary protein provides the precursors (tryptophan for serotonin, tyrosine for dopamine/norepinephrine) that feed the monoamine circuits disorganized by NEGR1 reduction. Omega-3 EPA/DHA supports neuronal membrane fluidity and monoamine receptor function. The dual mood-metabolic nature of NEGR1 means interventions supporting one pathway tend to benefit both.

Interactions

Rs2568958 is one of several SNPs tagging the same NEGR1 risk locus — rs34579341, rs2815752, rs11209948, and rs7531118 are all in moderate-to-high linkage disequilibrium with it. Users who have results for rs34579341 are reading from the same causal signal. The depression signal at NEGR1 interacts with BDNF Val66Met (rs6265): since NEGR1 drives hippocampal neurogenesis through the LIFR-Lcn2 axis that converges on BDNF, carriers of both G at rs2568958 and Met at rs6265 face compounded neurogenic impairment. COMT (rs4680) represents a relevant monoaminergic interaction given the dopamine and norepinephrine dysregulation documented in NEGR1-deficient animals.